OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

被引：3
作者：
Robson, Mark E. [1 ]
Im, Seock-Ah [2 ]
Senkus, Elzbieta [3 ]
Xu, Binghe [4 ]
Domchek, Susan [5 ]
Masuda, Norikazu [6 ]
Delaloge, Suzette [7 ]
Li, Wei [8 ]
Tung, Nadine [9 ]
Armstrong, Anne [10 ]
Wu, Wenting [11 ]
Goessl, Carsten [11 ]
Runswick, Sarah [12 ]
Conte, Pierfranco [13 ,14 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Med Univ Gdansk, Gdansk, Poland
[4] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[5] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA
[6] Natl Hosp Org, Osaka Natl Hosp, Osaka, Japan
[7] Inst Gustave Roussy, Villejuif, France
[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China
[9] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[11] AstraZeneca, Gaithersburg, MD USA
[12] AstraZeneca, Macclesfield, Cheshire, England
[13] Univ Padua, Padua, Italy
[14] Ist Oncol Veneto IRCCS, Padua, Italy
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT038
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
    Litton, J. K.
    Hurvitz, S. A.
    Mina, L. A.
    Rugo, H. S.
    Lee, K-H
    Goncalves, A.
    Diab, S.
    Woodward, N.
    Goodwin, A.
    Yerushalmi, R.
    Roch, H.
    Im, Y-H
    Eiermann, W.
    Quek, R. G. W.
    Usari, T.
    Lanzalone, S.
    Czibere, A.
    Blum, J. L.
    Martin, M.
    Ettl, J.
    ANNALS OF ONCOLOGY, 2020, 31 (11) : 1526 - 1535
  • [22] Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients
    Angell, Helen
    Ros, Vidalba Rocher
    Standifer, Nathan
    Lai, Zhongwu
    Gresty, Christopher
    Delord, Jean-Pierre
    De Jonge, Maja
    Postel-Vinay, Sophie
    Italiano, Antoine
    Krebs, Matthew G.
    Kaufman, Bella
    Park, Yeon Hee
    Domchek, Susan
    Herbolsheimer, Pia
    Hodgson, Darren
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [23] A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.
    Sun, Tao
    Shi, Yanxia
    Cui, Jiuwei
    Yin, Yongmei
    Ouyang, Quchang
    Liu, Qiang
    Zhang, Qingyuan
    Chen, Yiding
    Shao Zhimin
    Wang, Shouman
    Wang, Xiaojia
    Tong, Zhongsheng
    Zhong, Yahua
    Yan, Min
    Yan, Xi
    Wang, Chuan
    Yang, Haiyuan
    Li, Miao
    Xiang, Xiao
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)
    Dalvi, T.
    Gelmon, K. A.
    Dent, R.
    Pegram, M.
    Loibl, S.
    Tazir, Y.
    Milner, A.
    Lewis, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).
    Tutt, Andrew Nicholas James
    Kaufman, Bella
    Gelber, Richard D.
    Mc Fadden, Eleanor
    Goessl, Carsten Dietrich
    Viale, Giuseppe
    Arahmani, Amal
    Fumagalli, Debora
    Azim, Hatem Abdel
    Wu, Wenting
    Grocholewicz, Anna
    Costantino, Joseph P.
    Rastogi, Priya
    Garber, Judy Ellen
    Geyer, Charles E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
    Tutt, A.
    Kaufman, B.
    Garber, J.
    Gelber, R.
    McFadden, E.
    Goessl, C.
    Viale, G.
    Geyer, C.
    Zardavas, D.
    Arahmani, A.
    Fumagalli, D.
    De Azambuja, E.
    Ponde, N.
    Herbolsheimer, P.
    Wu, W.
    Constantino, J.
    Rastogi, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
    Schwartzberg, Lee S.
    Kiedrowski, Lesli A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [28] LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation
    Gelmon, K. A.
    Walker, G. P.
    Fisher, G. V.
    McCutcheon, S. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?
    Kuemmel, S.
    Jackisch, C.
    Mueller, V.
    Schneeweiss, A.
    Klawitter, S.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Clinical outcomes, treatment patterns and health resource utilization (HRU) among metastatic breast cancer (mbc) patients (pts) with germline BRCA mutation (gBRCAm)
    Quek, R.
    Mardekian, J.
    ANNALS OF ONCOLOGY, 2018, 29
12345